Research programme: anti-cancer therapeutics - Ascentage Pharma

Drug Profile

Research programme: anti-cancer therapeutics - Ascentage Pharma

Alternative Names: APG 2449; APG 2575; APG-1022

Latest Information Update: 11 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ascentage Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Apoptosis stimulants; Proto oncogene protein c met inhibitors; Proto oncogene protein c-akt inhibitors; Proto-oncogene protein c mdm2 inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 May 2018 Ascentage Pharma Group plans a phase I trial of APG 2575 for Haematological-malignancies (PO) in June 2018 (NCT03537482)
  • 06 Nov 2017 Ascentage Pharma announces intention to submit IND to China FDA for APG 2449 for Non-small cell lung cancer in the first quarter 2018 (Ascentage Pharma pipeline, November 2017)
  • 10 Jan 2017 Research programme: anti-cancer therapeutics - Ascentage Pharma is available for licensing as of 10 Jan 2017. http://www.ascentagepharma.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top